RESEARCH TRIANGLE PARK, N.C., CAMBRIDGE, England, and CONCORD, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, and N-of-One, Inc., a precision medicine oncology decision support company, are pleased to announce a new partnership to support analysis of patient cases for Inivata's InVision® liquid biopsy product line. This partnership will enable the delivery of clear, easy to interpret patient reports, providing physicians with a wealth of genomic information at their fingertips.
Inivata's revolutionary approach to ctDNA analysis delivers industry leading sensitivity across a broad panel of clinically relevant genomic alterations. The Next-Generation Sequencing-based method utilizes eTAm-Seq(TM), a proprietary amplification process, prior to sequencing and advanced analytical methods that enables the separation of true cancer mutations from background noise. The collaboration with N-of-One will provide each physician with an individualized liquid biopsy report based on their cancer patient's unique genomic signature. N-of-One's oncologists and Ph.D. scientists will also provide the analysis needed to assess current treatments, analyze potential novel mutations and allow the oncologists to make more informed decisions for treatment strategies. Inivata has also recently announced the launch of a large-scale, prospective clinical validation study in non-small cell lung cancer and additional studies are currently underway.
"N-of-One's experience in curating complex genomic information and translating this data into clinically relevant results on tens of thousands of patients has enabled them to develop a market-leading database and unparalleled expertise. We are excited to access their capabilities to ensure we provide physicians with the most actionable information in our easy to interpret report," said Michael Stocum, CEO of Inivata.
N-of-One will support Inivata's liquid biopsy assay by providing oncologists and pathologists with the most relevant oncology treatment options through the analysis of each patient's unique molecular profile. The N-of-One solution will integrate the interpretation of multiple molecular tests on a patient to provide a comprehensive view of the cancer and, leveraging N-of-One's proprietary database, will identify individualized treatment options, including clinical trials for consideration by the oncologist. N-of-One's experience in oncology, and specifically liquid biopsies, makes them uniquely capable of interpreting the Inivata liquid biopsy test.
"We are pleased to partner with Inivata in support of the launch of their revolutionary ctDNA platform capabilities," said Chris Cournoyer, CEO of N-of-One. "Pairing Inivata's highly sensitive analysis of actionable mutations with N-of-One's ability to analyze the data of novel mutations has the potential to help guide more personalized treatment decisions for patients prior to and throughout the cancer care continuum.
Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata's Invision® ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. In 2016, Inivata opened a CLIA lab in Research Triangle Park, NC and launched a large-scale, prospective clinical validation study of the Company's ctDNA analysis in lung cancer. For more information and a full listing of investors, please go to www.inivata.com. Follow us on Twitter @Inivata.
N-of-One is a leader in identifying patient-specific treatment options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate genomic data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One's actionable solutions have provided treatment options, including clinical trials, to clinicians for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. For more information, please visit www.n-of-one.com or call 617-202-9808.
Media Contacts: Liz Macfadyen Liz.firstname.lastname@example.org +44 (0)7739462323 Consilium Strategic Communications Chris Gardner/Laura Thornton Email: email@example.com Phone: +44 (0)20 3709 5700 Lisa Rivero Lisa.firstname.lastname@example.org 617-761-6780